Yuhri Miyawaki.

Yuhri Miyawaki, M.Sc., Atsuo Suzuki, M.Sc., Junko Fujita, B.Sc., Asuka Maki, B.Sc., Eriko Okuyama, B.Sc., Moe Murata, B.Sc., Akira Takagi, Ph.D., Takashi Murate, M.D., Ph.D., Shinji Kunishima, Ph.D., Michio Sakai, M.D., Kohji Okamoto, M.D., Ph.D., Tadashi Matsushita, M.D., Ph.D., Tomoki Naoe, M.D., Ph.D., Hidehiko Saito, M.D., Ph.D., and Tetsuhito Kojima, M.D., Ph.D.: Brief Report: Thrombosis from a Prothrombin Mutation Conveying Antithrombin Resistance Patients with hereditary thrombophilia often present with unusual clinical episodes of venous thrombosis in a young age and recurrence in atypical vessels, often with a family group history of the problem.1 Genetic studies of hereditary thrombophilia have revealed two types of genetic defects: loss-of-function mutations in the natural anticoagulants antithrombin, proteins C, and proteins S, along with gain-of-function mutations in procoagulant factors V and II .2 To date, several genetic defects have been found in family members with hereditary thrombophilia, but there might be many undiscovered causative mutations.3 Here, we describe a complete case of hereditary thrombosis induced by a novel mechanism of antithrombin resistance, a gain-of-function mutation in the gene encoding the clotting factor prothrombin .More info on the Environmental Burden of Disease study is an essential and well-documented mental health outcome among significantly injured civilian and military survivors of trauma.1-10 Increasing recognition of the profound and prolonged detrimental effects on health and wellness status and quality of life when PTSD develops in the aftermath of critical physical injury or exposure to traumatic events has made its prevention a focus of research on trauma-related outcomes.2-4,11-14 The secondary prevention of PTSD with pharmacotherapy in the aftermath of main trauma is a newly evolving and essential area of research.